Objective: to assess safety and efficacy of the available oral anti diabetic Drugs during Ramadan 2016 in Sohag Governorate . Methodology: This study was conducted on 90 type II Diabetic patients attending to outpatient Endocrinology clinic in Sohag University Hospital, on oral treatment classified into 5groups,as following , 20 (22.22%)patients on Metformin(Group I),30 (33.33%)patients on Sulphonylureas with or without metformin(Group II), 18 (20%) patients on Dipeptidyl peptidase-4 inhibitors with or without metformin (Group III),12 (13.33% ) patients on Thiazolidinedoines with or without metformin (Group V),10 (10%) patients on combinations of more than two drugs (Group VI), Mean age of patients is 59.93±7.87years, (61.11%)of them were females,(38.89%) of them were male patients and Mean duration of diabetes is 4.52±2.45(range 1:10).follow up of the patient was done by Wight changes, measuring blood sugar ,asses Hba1c ,and renal function also was done before and during ramadan. Results: In this study we found a significant decrease in Hba1c after Ramadan with Group III (DPP4I) compared with other Groups also we found the number of hypoglycemic episodes of all groups about 10 (11.11%), more with Group II (SUs) about (9) patients developed hypoglycemia of whom 30, compared with other groups while lower number of hypoglycemia was found with Group III (DPP4I),about one patient developed hypoglycemia, also we found the number of non fasted days more with SUs,(range 2-10) also we found no body weight changes more with Group III (DPP4I) while body weight gain occurred with Group II (SUs) about 1-4Kgs . In conclusion, Ramadan represents one of challenging issues for health care providaers all over the world . DPP4 inhibitors may considered favorable for use during and after Ramadan due to their lower rate of hypoglycemic events and weight neutral/loss effect during and after Ramadan .
Introduction
Fasting during Ramadan, a holy month of Islam, is an obligatory duty for all healthy adult Muslims. Around 9 % is the prevalence of diabetes worldwide and the estimated number of diabetic patients reached more than 4 hundred millions according to the latest edition of the IDF diabetes Atlas. Egypt has 8th highest rate of diabetes (7.8 millions) globally and is the first in the Arab world and in Africa, (1 In this study we found a significant decrease in Hba1c after Ramadan with Group III (DPP4I) compared with other Groups also we found the number of hypoglycemic episodes of all groups about 10 (11.11%), more with Group II (SUs) about (9) patients developed hypoglycemia of whom 30, compared with other groups while lower number of hypoglycemia was found with Group III (DPP4I),about one patient developed hypoglycemia, also we found the number of non fasted days more with SUs,(range 2-10) also we found no body weight changes more with Group III (DPP4I) while body weight gain occurred with Group II (SUs) about 1-4Kgs . This study supported with the same result as was in :
In STEADFAST study (randomized study), (3 16 .8%, and 14.0% observed in subjects treated with glibenclamide, glimepiride, and gliclazide, respectively. By country, the highest incidence of hypoglycaemia was reported by subjects from Israel (40%) followed by those from Malaysia (24%), the UAE (18%), India (13%), and Saudi Arabia (10%). The overall incidence of severe hypoglycaemic events (i.e., events requiring medical or non-medical assistance) was 6.7%, with the highest incidence occurring in the glibenclamide group) ,this study differ from our study in , this study was done only on one group,(patients using sulphonylureas with or without metformin),while this study was done on 5 groups (patients using metformin ,sulphonylureas ,DPP4I,TZDS,and combination of more than two drugs ).
In vildagliptin therapy and hypoglycemia in Muslims type II during Ramadan study. ,at least one hypoglycaemic event (defined as blood glucose < 3.5 mmol/l with or without symptoms) was recorded in two patients receiving vildagliptin (7.7%) and 16 patients receiving gliclazide [61.5%; difference between groups −53.8%, 95% confidence interval (CI) −74.9 to −26.3, p < 0.001]. Vildagliptin was associated with a reduction in the mean number of hypoglycaemic events during Ramadan compared with before Ramadan, whereas gliclazide was associated with an increase (least squares mean difference between groups −0.66, 95% CI −1.20 to −0.13, p = 0.0168). Both gliclazide and vildagliptin were associated with similar reductions in Hba1c and a small, but insignificant, increase in weight).
In study of safety and efficacy of dpp4i and metformin as initial combination therapy and as a mono therapy in patient with type II DM, (14) China 2013, showing more reduction in Hba1c , body weight and no hypoglycemic event with combination therapy than metformin alone ., in this study we found no changes in Hba1c ,body weight with metformin alone and we found low significant reduction with combination may be due to miss use of drugs during Ramadan , this study differ in which not in fasting days not in Ramadan,
In EPIDIAR study , (15 
Limitations:
This was an observational study and as such subjects were not randomized to treatments. While baseline measures appeared comparable, it is possible that differences in measured and unmeasured patient characteristics (e.g., measures of glycemic control) could partially explain these results. this study leak observation and follow up of diet and exercise and there effect on diabetic patients during Ramadan, also our study included small number of patients . Conclusion: Ramadan represents one of the challenging issues for health care providers all over the world. DPP-4 inhibitors may considered favorable for use during and after Ramadan due to their lower rate of hypoglycemic events and weight neutral/loss effect during and after Ramadan. ,estimate significant abnormality. As regard number of hypoglycemic events mostly in group II (sulphonylureas) 9 patients have hypoglycemia from30 patients and range of non-fasted days with the same group was (2:10).also hyperglycemia was found with all groups ,13patients (14.44%) . with analysis of HBA1C ,improvement mostly was group 3 more than other groups. also with analysis body weight change, showing little changes especially with group 2 (SUs) on other hand about 80% no body changes with other groups. with analysis of s.creatinine significant changes occurred with dpp4i and combinations drugs
